Q2 Earnings Estimate for Pharvaris Issued By HC Wainwright

Pharvaris N.V. (NASDAQ:PHVS) – HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for shares of Pharvaris in a report issued on Thursday, May 14th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.69) per share for the quarter, up from their previous estimate of ($0.89). HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($3.35) per share. HC Wainwright also issued estimates for Pharvaris’ Q3 2026 earnings at ($0.76) EPS, Q4 2026 earnings at ($0.83) EPS, FY2026 earnings at ($2.98) EPS, FY2027 earnings at ($2.41) EPS, FY2028 earnings at ($0.02) EPS, FY2029 earnings at $3.23 EPS and FY2030 earnings at $6.59 EPS.

Other research analysts have also recently issued reports about the company. Wall Street Zen upgraded Pharvaris from a “strong sell” rating to a “sell” rating in a report on Saturday. Royal Bank Of Canada lowered their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Wedbush boosted their target price on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Citizens Jmp lowered their target price on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. Finally, UBS Group set a $74.00 target price on Pharvaris in a report on Wednesday, May 13th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $49.18.

Pharvaris Trading Down 5.2%

PHVS stock opened at $28.81 on Tuesday. Pharvaris has a 12-month low of $15.46 and a 12-month high of $33.33. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of -9.06 and a beta of -2.34. The business’s 50-day moving average is $28.20 and its 200 day moving average is $26.63.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.12.

Institutional Trading of Pharvaris

Several institutional investors have recently made changes to their positions in the company. General Atlantic L.P. raised its position in shares of Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after buying an additional 500,000 shares during the period. Foresite Capital Management IV LLC raised its position in shares of Pharvaris by 8.3% during the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after buying an additional 368,000 shares during the period. venBio Partners LLC raised its position in shares of Pharvaris by 8.2% during the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after buying an additional 350,000 shares during the period. Deerfield Management Company L.P. raised its position in shares of Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after buying an additional 425,000 shares during the period. Finally, Commodore Capital LP raised its position in shares of Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after buying an additional 507,043 shares during the period.

Insider Buying and Selling

In other news, insider Peng Lu sold 15,000 shares of Pharvaris stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.24, for a total transaction of $453,600.00. Following the sale, the insider owned 66,083 shares of the company’s stock, valued at approximately $1,998,349.92. The trade was a 18.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Anne Lesage sold 21,700 shares of Pharvaris stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.26, for a total transaction of $656,642.00. Following the sale, the insider directly owned 56,450 shares in the company, valued at approximately $1,708,177. The trade was a 27.77% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 150,659 shares of company stock valued at $4,489,587.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.